Conclusions

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 148 CE courses, most popular
$95Add to cart
Pick Your Courses
Up to 8 CE hours
$50Add to cart
Individual course$20Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Advances in Noninvasive Prenatal Testing For Down Syndrome and other Trisomies (online CE course)
Conclusions

In summary, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population. However, CVS and amniocentesis are still considered diagnostic tests for fetal aneuploidy. Currently, NIPT that employs cfDNA is not considered diagnostic. Women having a positive NIPT result should be offered conventional invasive diagnostic testing such as CVS or amniocentesis for confirmation. With an abnormal ultrasound finding that suggests an increased risk of aneuploidy, clinicians may decide to include cfDNA testing as additional evidence of possible aneuploidy, however, the patient should undergo diagnostic testing for actual confirmation.